Multisite international collaborative clinical trials in mania

International Journal of Neuropsychopharmacology

Volumn 14, Issue 8, 2011, Pages 1013-1016

  Vázquez, Gustavo ^a,b   Baldessarini, Ross J ^b,c   Yildiz, Ayşegül ^b,d   Tamayo, Jorge ^e   Tondo, Leonardo ^b,c,f   Salvatore, Paola ^b,c,g  

^a UNIVERSITY OF PALERMO   (Argentina)

^b MCLEAN HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d DOKUZ EYLUL UNIVERSITY   (Turkey)

^e UNIVERSIDAD CES   (Colombia)

^f Lucio Bini Mood Disorder Center   (Italy)

^g UNIVERSITY OF PARMA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; PLACEBO; ZIPRASIDONE;

AFTERCARE; ARTICLE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SYNTHESIS; ECONOMIC DEVELOPMENT; EDUCATIONAL STATUS; EMPLOYMENT; ETHICS; HEALTH SERVICE; HUMAN; INDIA; KNOWLEDGE; MANIA; META ANALYSIS (TOPIC); MULTISITE INTERNATIONAL COLLABORATIVE CLINICAL TRIAL; PRIORITY JOURNAL; RUSSIAN FEDERATION; SKILL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

BIPOLAR DISORDER; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DRUG APPROVAL; HUMANS; INTERNATIONALITY; MULTICENTER STUDIES AS TOPIC;

EID: 80052966858     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1017/S1461145711000447     Document Type: Article

References (25)

1. Anello C, O'Neill RT, Dubey S (2005). Multicenter trials: US regulatory perspective. Statistical Methods in Medical Research 14, 303-318.
2. Demol P, Weihrauch TR (1997). Multinational clinical therapy studies: design, management and costs. Medizinische Klinik 92, 117-123.
3. Glickman SW, McHutchison JG, Peterson ED, Cairns CB, et al. (2009). Ethical and scientific implications of the globalization of clinical research. New England Journal of Medicine 360, 816-823.
4. Gopal S, Steffens DC, Kramer ML, Olsen MK (2005). Symptomatic remission in patients with bipolar mania: results from a double-blind, placebo-controlled trial of risperidone monotherapy. Journal of Clinical Psychiatry 66, 1016-1020. (Pubitemid 41191794)
5. Greco D, Diniz NM (2008). Conflicts of interest in research involving human beings. International Journal of Bioethics 19, 143-154.
6. Ibia E, Binkowitz B, Saillot J-L, Talerico S, et al. (2010). Ethical considerations in industry sponsored multiregional clinical trials. Pharmaceutical Statistics 9, 230-241.
7. ICH Guideline (2002). International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use: ICH Harmonized Tripartite Guideline (ICH Topic E6[R1]), June 1996, revised July 2002. Geneva: International Federation of Pharmaceutical Manufacturers & Associations (www.ich.org/LOB/media/MEDIA482.pdf). Accessed 11 Deccember 2010.
8. Jones B, Teather D, Wang J, Lewis JA (1998). A comparison of various estimators of a treatment difference for a multicentre clinical trial. Statistics in Medicine 30, 1767-1777. (Pubitemid 28409931)
9. Karno M, Jenkins JH (1993). Cross cultural issues in the course and treatment of schizophrenia. Psychiatric Clinics of North America 16, 339-350. (Pubitemid 23174757)
10. Keck Jr. PE, Marcus R, Tourko Dimitris S, Ali M, Liebeskind A, et al. (2003). Placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 160, 1651-1658. (Pubitemid 41079552)
11. Kemp AS, Schooler NR, Kalali AH, Alphs L, et al. (2010). What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophrenia Bulletin 36, 504-509.
12. Lopez-Ibor Jr. JJ (2003). Cultural adaptations of current psychiatric classifications: are they the solution? Psychopathology 36, 114-119. (Pubitemid 36829107)
13. Pope Jr. HG, McElroy SL, Keck Jr. PE, Hudson JI (1991). Valproate in the treatment of acute mania. A placebo-controlled study. Archives of General Psychiatry 48, 62-68.
14. Robins LN (1985). Epidemiology: reflections on testing the validity of diagnostic interviews. Archives of General Psychiatry 41, 89-117.
15. Saillot J, Paxton M (2009). Industry efforts at simultaneous global development. Drug Information Journal 43, 339-347.
16. Smulevich AB, Khanna S, Eerdekens M, Karcher K, et al. (2005). Acute and continuation risperidone monotherapy in bipolar mania: 3-week placebo-controlled trial followed by 9-week double-blind trial of risperidone and haloperidol. European Neuropsychopharmacology 15, 75-84. (Pubitemid 39574402)
17. Tamayo JM, Mazzotti G, Tohen M, Gattaz WF, et al. (2007). Outcomes for Latin American vs. white patients suffering from acute mania in a randomized, double-blind trial comparing olanzapine and haloperidol. Journal of Clinical Psychopharmacology 27, 126-134. (Pubitemid 46603546)
18. Uesaka H (2009). Sample size allocation to regions in a multiregional trial. Journal of Biopharmaceutical Statistics 19, 580-594.
19. U.S. FDA (1998). Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products, May 1998 (www.fda.gov/Guidance for Industry Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products/ucm078749.pdf). U.S. Food and Drug Administration. Accessed March 2011.
20. Vieta E, Pappadopulos E, Mandel FS, Lombardo I (2011). Impact of geographical and cultural factors on clinical trials in acute mania: lessons from a ziprasidone and haloperidol placebo-controlled study. International Journal of Neuropsychopharmacology. Published online: 14 March 2011. doi:10.1017/S146114571100040x.
21. Westermeyer J, Janca A (1997). Language, culture and psychopathology: conceptual and methodological issues. Transcultural Psychiatry 34, 291-311.
22. Yildiz A, Guleryuz S, Ankerst DP, Ongür D, et al. (2008). Protein kinase C inhibition in the treatment of mania: a double-blind, placebo-controlled trial of tamoxifen. Archives of General Psychiatry 65,55-163.
23. Yildiz A, Vieta E, Leucht S, Baldessarini RJ (2011a). Efficacy of anti-manic treatments: meta-analysis of randomized controlled trials. Neuropsychopharmacology 36, 375-389.
24. Yildiz A, Vieta E, Tohen M, Baldessarini RJ (2011b). Factors modifying drug and placebo responses in randomized trials for bipolar mania. International Journal of Neuropsychopharmacology. Published online: 7 February 2011. doi:10.1017/S1461145710001641.
25. Zarate Jr. CA, Singh JB, Carlson PJ, Quiroz J, et al. (2007). Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disorders 9, 561-567.